{"id":"NCT02914561","sponsor":"Galapagos NV","briefTitle":"Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease","officialTitle":"Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-31","primaryCompletion":"2022-11-11","completion":"2022-11-11","firstPosted":"2016-09-26","resultsPosted":"2023-12-18","lastUpdate":"2023-12-18"},"enrollment":1372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Filgotinib","otherNames":["GS-6034","GLPG0634"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cohort A: Filgotinib 200 (mg) (Induction Study)","type":"EXPERIMENTAL"},{"label":"Cohort A: Filgotinib 100 mg (Induction Study)","type":"EXPERIMENTAL"},{"label":"Cohort A: Placebo (Induction Study)","type":"PLACEBO_COMPARATOR"},{"label":"Cohort B: Filgotinib 200 mg (Induction Study)","type":"EXPERIMENTAL"},{"label":"Cohort B: Filgotinib 100 mg (Induction Study)","type":"EXPERIMENTAL"},{"label":"Cohort B: Placebo (Induction Study)","type":"PLACEBO_COMPARATOR"},{"label":"Filgotinib 200 mg to Filgotinib 200 mg (Maintenance Study)","type":"EXPERIMENTAL"},{"label":"Filgotinib 200 mg to Placebo (Maintenance Study)","type":"EXPERIMENTAL"},{"label":"Filgotinib 100 mg to Filgotinib 100 mg (Maintenance Study)","type":"EXPERIMENTAL"},{"label":"Filgotinib 100 mg to Placebo (Maintenance Study)","type":"EXPERIMENTAL"},{"label":"Placebo to Placebo (Maintenance Study)","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced.\n\nParticipants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Study GS-US-419-3896).","primaryOutcome":{"measure":"Induction Study: Percentage of Participants Who Achieved Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10","timeFrame":"Week 10","effectByArm":[{"arm":"Cohort A: Filgotinib 200 mg (Induction Study)","deltaMin":32.9,"sd":null},{"arm":"Cohort A: Filgotinib 100 mg (Induction Study)","deltaMin":25.7,"sd":null},{"arm":"Cohort A: Placebo (Induction Study)","deltaMin":19.8,"sd":null},{"arm":"Cohort B: Filgotinib 200 mg (Induction Study)","deltaMin":26.7,"sd":null},{"arm":"Cohort B: Filgotinib 100 mg (Induction Study)","deltaMin":16.7,"sd":null},{"arm":"Cohort B: Placebo (Induction Study)","deltaMin":14.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0017"},{"comp":"OG001 vs OG002","p":"0.1730"},{"comp":"OG003 vs OG005","p":"0.0023"},{"comp":"OG004 vs OG005","p":"0.6038"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":513,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Croatia","Czechia","France","Georgia","Germany","Greece","Hong Kong","Hungary","Iceland","India","Ireland","Israel","Italy","Japan","Malaysia","Netherlands","New Zealand","Norway","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovakia","South Africa","South Korea","Spain","Sri Lanka","Sweden","Switzerland","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["39637881"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":222},"commonTop":["Crohn's disease","Headache","Abdominal pain","Nausea","Nasopharyngitis"]}}